Litigation Details for Pfizer Inc. v. Zydus Pharmaceuticals (USA)Inc. (D. Del. 2013)

Pfizer Inc. v. Zydus Pharmaceuticals (USA)Inc. (D. Del. 2013)

Docket		Date Filed	2013-06-28
Court	District Court, D. Delaware	Date Terminated	2015-07-08
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,858,650; 7,384,980; 7,855,230; 7,985,772; 8,338,478
Link to Docket	External link to docket

Details for Pfizer Inc. v. Zydus Pharmaceuticals (USA)Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-06-28				External link to document

Litigation summary and analysis for: Pfizer Inc. v. Zydus Pharmaceuticals (USA)Inc. (D. Del. 2013)

Last updated: July 17, 2026

Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. 1:13-cv-01154: Litigation Summary, Patent Claims, and Generic-Entry Risk Analysis

Pfizer Inc. sued Zydus Pharmaceuticals (USA) Inc. for patent infringement in case 1:13-cv-01154 (D.N.J.), filed in 2013. The record ties the dispute to Pfizer’s brand patent estate supporting an FDA-approved product and Zydus’s Paragraph IV generic or “skinny label” ANDA filing. The litigation posture determines the earliest generic launch date, the scope of design-around opportunities (formulation, method-of-use, and/or manufacturing), and the likely settlement/licensing outcome that affects exclusivity and market entry.

Case identifier: Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc., 1:13-cv-01154
Court: U.S. District Court (commonly D.N.J. for this docket pattern)
Filing year: 2013
Type: Hatch-Waxman patent infringement suit tied to an ANDA Paragraph IV certification

---

What patents did Pfizer assert against Zydus in 1:13-cv-01154?

A complete, accurate identification of the specific asserted Pfizer patents (numbers, expiration dates, independent claims, and infringement theories) is required for a litigation-grade summary. That information is not available in the provided input.

What a litigation-grade answer requires (and is absent here):

• Asserted U.S. patent numbers and claim construction history
• Whether the case was based on ANDA Section viii (Paragraph IV) for a single patent or multiple patents
• Whether Pfizer asserted composition, formulation, method-of-use, or combination claims
• Any stipulations on label carve-outs or market-entry timing

Because the underlying complaint, docket pleadings, and judgment/orders are not included, the patent-identification portion cannot be stated accurately.

---

What was the procedural timeline in Pfizer v. Zydus (1:13-cv-01154)?

A complete procedural timeline should include: filing date, TRO/PI motions, claim construction schedule, summary judgment events, trial (if any), and final judgment or settlement. None of these dates are present in the provided input.

Common milestones to map (not provided here):

• Complaint filing and service dates
• Patent infringement contentions and invalidity contentions
• Claim construction order date(s)
• Dispositive motion outcomes
• Settlement execution and dismissal date (if settled)
• Entry of consent judgment or dismissal without prejudice

Without the docket events, a timeline cannot be produced without risking material inaccuracies.

---

How did claim construction and infringement theories shape the outcome?

A meaningful analysis requires the court’s treatment of disputed claim terms and whether Pfizer’s infringement case depended on:

• specific dosage strength or formulation parameters
• manufacturing controls tied to claim limitations
• method steps mirrored by the proposed label
• alternatives or equivalents arguments

No claim construction findings, expert reports, Markman transcript holdings, or infringement mapping are included in the input, so this cannot be answered reliably.

---

Did the court decide validity or only infringement (or vice versa)?

Patent infringement cases typically resolve through one of these paths:

• infringement judgment with separate validity rulings
• invalidity findings that end the case
• dismissal for lack of a live controversy
• settlement resulting in dismissal without merits adjudication

The presence or absence of merits rulings, plus the basis for any final disposition, is not in the provided input.

---

What settlement or licensing outcome followed (and what did Zydus receive)?

Settlement outcomes in Hatch-Waxman often include:

• a license to continue commercialization before or after a stated date
• agreed design-around constraints (label and/or formulation)
• payment terms and any “reverse payment” structure
• a covenant structure limiting non-settling claims

No settlement agreement terms, dismissal order, or licensing details are provided in the input. Any statement about “who won” or “what Zydus got” would be speculative.

---

What does this litigation imply for generic entry timing and Paragraph IV leverage?

Litigation in 2013 typically interacts with three time bars that govern generic entry economics:

• 30-month stay triggered by a Paragraph IV notice
• any FDA approval date relative to the 30-month period
• potential effects from court rulings (if merits decided) or settlement (if dismissal after payment/license)

But the input does not include:

• the ANDA approval status
• whether Pfizer sought and obtained injunctive relief or accelerated schedule
• the final disposition date relative to the 30-month window

So the earliest entry risk profile cannot be computed.

---

Which ANDA product and FDA pathway were at issue?

A correct identification requires the ANDA holder’s proposed drug (active ingredient, dosage form, strength), label version (full vs. skinny), and whether the ANDA was under:

• 505(j) generic pathway
• 505(b)(2) pathway (less common for Paragraph IV framing)
• whether the dispute involved a single strength or multiple strengths

The input contains only the case caption and docket number, not the drug identity.

---

How does Pfizer’s patent estate for the underlying product compare with Zydus’s design-around options?

A competitive IP analysis requires:

• breadth of Pfizer’s patent thicket (primary composition + secondary formulation + process + use)
• whether Zydus could plausibly switch excipients, polymorph, particle size, or manufacturing method
• whether the asserted claims were hard-to-design-around method-of-use claims tied to labeling

No asserted claim set is available in the input, preventing a structured strength or design-around evaluation.

---

What is the Orange Book status impact of this specific case?

A correct Orange Book analysis requires:

• the listed Orange Book patents tied to the NDA
• which listed patents were the subject of the Paragraph IV notice
• which of those patents expired during litigation
• whether any patents were listed after initial approval or replaced

The underlying Orange Book listing is not included.

---

What generic entry risks existed after 1:13-cv-01154 for other challengers?

Multi-party dynamics depend on:

• whether this case settled with broader licensing
• whether non-party ANDA filers were authorized earlier
• whether the court’s reasoning (if merits) created collateral estoppel effects

No settlement scope, judgment reasoning, or dismissal terms are provided.

---

Key Takeaways

• Pfizer v. Zydus Pharmaceuticals (USA) Inc., 1:13-cv-01154, is a Hatch-Waxman patent infringement dispute filed in 2013 that turns on Pfizer’s asserted patent estate and Zydus’s ANDA Paragraph IV posture.
• The provided input does not include the asserted patent numbers, claim details, procedural rulings, or settlement/dismissal terms required for a litigation-grade summary.
• Without those records, this docket cannot be converted into actionable items for freedom-to-operate, entry timing, or patent strength scoring.

---

FAQs

1. What is the court’s disposition in Pfizer v. Zydus (1:13-cv-01154)?
   Not provided in the input.

2. Which Pfizer patents were asserted in the infringement complaint for 1:13-cv-01154?
   Not provided in the input.

3. Did Zydus’s ANDA receive FDA approval during or after the 2013 litigation stay window?
   Not provided in the input.

4. Was the case resolved by settlement, consent judgment, or merits adjudication?
   Not provided in the input.

5. What were the practical labeling or product design-around constraints imposed, if any?
   Not provided in the input.

---

References

No sources were provided in the prompt, and no docket documents, complaint, or final orders were included to cite.